Recursion (RXRX) to Report Q1 Earnings: What's in the Cards? [Yahoo! Finance]
Recursion Pharmaceuticals, Inc. - Class A (RXRX)
Company Research
Source: Yahoo! Finance
The Zacks Consensus Estimate for first-quarter revenues is pinned at $13.4 million, suggesting a 10% increase from the year-ago quarter's reported figure. Let us see how things have shaped up for the quarterly release of this TechBio company that decodes biology and chemistry to industrialize drug discovery. Factors to Consider In the absence of a marketed product in the company's commercial portfolio, Recursion only recognizes collaboration revenues from its partners. The company has ongoing collaboration agreements with pharma giants like Roche and Bayer to develop candidates for several oncology indications, with differentiated mechanisms of action. RXRX is also currently collaborating with NVIDIA Corporation, the worldwide leader in visual computing technologies, to accelerate the development program of its novel AI foundation models for biology and chemistry. Revenues from such existing collaborations are likely to have recorded year-over-year growth for Recursion. Th
Show less
Read more
Impact Snapshot
Event Time:
RXRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RXRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RXRX alerts
High impacting Recursion Pharmaceuticals, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
RXRX
News
- Nvidia Recently Bought 5 Artificial Intelligence (AI) Stocks, and 1 Is Absolutely Soaring [Yahoo! Finance]Yahoo! Finance
- Recursion Announces Completion of NVIDIA-Powered BioHive-2, the Largest Supercomputer in Pharmaceutical IndustryGlobeNewswire
- Cathie Wood Is Buying This Under-the-Radar AI Stock [Yahoo! Finance]Yahoo! Finance
- Recursion Pharmaceuticals CEO explains how AI could make drug development faster and less costly [CNBC]CNBC
- Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
RXRX
Earnings
- 5/9/24 - Beat
RXRX
Sec Filings
- 5/17/24 - Form 4
- 5/17/24 - Form 4
- 5/17/24 - Form 4
- RXRX's page on the SEC website